Mettler-Toledo International Inc. (0K10.L)
USD 1085.39
(2.02%)
USD 1085.39
(2.02%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.16 Billion USD | 1.74% |
| 2022 | 2.13 Billion USD | 18.31% |
| 2021 | 1.8 Billion USD | 25.63% |
| 2020 | 1.43 Billion USD | 3.9% |
| 2019 | 1.37 Billion USD | 33.35% |
| 2018 | 1.03 Billion USD | 5.6% |
| 2017 | 979.84 Million USD | 9.6% |
| 2016 | 894.03 Million USD | 51.63% |
| 2015 | 589.62 Million USD | 30.46% |
| 2014 | 451.95 Million USD | 8.04% |
| 2013 | 418.33 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.08 Billion USD | -4.99% |
| 2024 Q2 | 2.05 Billion USD | -1.38% |
| 2023 FY | 2.19 Billion USD | 3.08% |
| 2023 Q4 | 2.19 Billion USD | 4.16% |
| 2023 Q1 | 2.12 Billion USD | -0.37% |
| 2023 Q2 | 2.15 Billion USD | 1.41% |
| 2023 Q3 | 2.1 Billion USD | -2.06% |
| 2022 Q1 | 1.87 Billion USD | 3.95% |
| 2022 Q4 | 2.13 Billion USD | 7.67% |
| 2022 FY | 2.13 Billion USD | 18.31% |
| 2022 Q2 | 1.92 Billion USD | 2.99% |
| 2022 Q3 | 1.97 Billion USD | 2.64% |
| 2021 Q3 | 1.69 Billion USD | 2.3% |
| 2021 FY | 1.8 Billion USD | 25.63% |
| 2021 Q1 | 1.61 Billion USD | 14.7% |
| 2021 Q2 | 1.65 Billion USD | 2.57% |
| 2021 Q4 | 1.8 Billion USD | 6.37% |
| 2020 Q3 | 1.22 Billion USD | 1.93% |
| 2020 Q2 | 1.2 Billion USD | -23.49% |
| 2020 Q1 | 1.57 Billion USD | 16.23% |
| 2020 FY | 1.43 Billion USD | 3.9% |
| 2020 Q4 | 1.4 Billion USD | 14.62% |
| 2019 FY | 1.37 Billion USD | 33.35% |
| 2019 Q4 | 1.35 Billion USD | 9.43% |
| 2019 Q3 | 1.23 Billion USD | 2.74% |
| 2019 Q2 | 1.2 Billion USD | 7.21% |
| 2019 Q1 | 1.12 Billion USD | 8.56% |
| 2018 Q2 | 1.07 Billion USD | 7.94% |
| 2018 Q1 | 993.59 Million USD | 1.4% |
| 2018 FY | 1.03 Billion USD | 5.6% |
| 2018 Q4 | 1.03 Billion USD | -0.95% |
| 2018 Q3 | 1.04 Billion USD | -2.59% |
| 2017 Q2 | 969.38 Million USD | 0.59% |
| 2017 Q4 | 979.84 Million USD | -8.36% |
| 2017 FY | 979.84 Million USD | 9.6% |
| 2017 Q1 | 963.68 Million USD | 7.79% |
| 2017 Q3 | 1.06 Billion USD | 10.3% |
| 2016 FY | 894.03 Million USD | 51.63% |
| 2016 Q3 | 847.8 Million USD | 18.71% |
| 2016 Q1 | 699.25 Million USD | 18.59% |
| 2016 Q4 | 894.03 Million USD | 5.45% |
| 2016 Q2 | 714.2 Million USD | 2.14% |
| 2015 Q3 | 622.79 Million USD | -1.36% |
| 2015 FY | 589.62 Million USD | 30.46% |
| 2015 Q4 | 589.62 Million USD | -5.33% |
| 2015 Q2 | 631.36 Million USD | 19.34% |
| 2015 Q1 | 529.03 Million USD | 17.05% |
| 2014 Q1 | 470.53 Million USD | 12.48% |
| 2014 Q2 | 471.07 Million USD | 0.11% |
| 2014 Q3 | 488.56 Million USD | 3.71% |
| 2014 Q4 | 451.95 Million USD | -7.49% |
| 2014 FY | 451.95 Million USD | 8.04% |
| 2013 Q4 | 418.33 Million USD | 2.81% |
| 2013 Q2 | 468.15 Million USD | 4.65% |
| 2013 Q3 | 406.88 Million USD | -13.09% |
| 2013 Q1 | 447.37 Million USD | 0.0% |
| 2013 FY | 418.33 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -5833.241% |
| Dynavax Technologies Corporation | 256.91 Million USD | -743.772% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -4921.82% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 77.31% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -5120.144% |
| Perrigo Company plc | 4.07 Billion USD | 46.782% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -3645.799% |
| Illumina, Inc. | 2.26 Billion USD | 4.166% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 93.792% |
| Nektar Therapeutics | 230.4 Million USD | -840.868% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -216676.9% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 84.767% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -1147.615% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -7931.749% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -91.182% |
| Waters Corporation | 2.35 Billion USD | 7.97% |
| Biogen Inc. | 7.33 Billion USD | 70.459% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -5589.085% |
| Adicet Bio, Inc. | 17.7 Million USD | -12145.207% |
| Evolus, Inc. | 126.54 Million USD | -1613.028% |
| bluebird bio, Inc. | 330.32 Million USD | -556.251% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -70419.486% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -300.736% |
| FibroGen, Inc. | 170.45 Million USD | -1171.754% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 20.74% |
| Homology Medicines, Inc. | 44.05 Million USD | -4820.709% |
| Geron Corporation | 85.89 Million USD | -2423.625% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 9.602% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -10279.932% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -387.075% |
| Myriad Genetics, Inc. | 145 Million USD | -1395.013% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 19.798% |
| OPKO Health, Inc. | 326.56 Million USD | -563.811% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -171945.159% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -1779.362% |
| Zoetis Inc. | 6.8 Billion USD | 68.135% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -49145.093% |
| Exelixis, Inc. | 189.94 Million USD | -1041.267% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -168.155% |
| uniQure N.V. | 138.4 Million USD | -1466.205% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -5868.034% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -1063.141% |
| Verastem, Inc. | 41.55 Million USD | -5116.375% |
| Imunon, Inc. | 1.13 Million USD | -190173.178% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -49.137% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | -55.194% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -406.015% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -1435508.609% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -44.59% |
| TG Therapeutics, Inc. | 110.79 Million USD | -1856.559% |
| Blueprint Medicines Corporation | 774.12 Million USD | -180.029% |
| Insmed Incorporated | 1.2 Billion USD | -80.048% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -3703.904% |
| Incyte Corporation | 38.28 Million USD | -5561.893% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -147.039% |